Skip to main content

CTOS 2023 Main banner

Schedule at a Glance

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Title

Browse by Poster Title

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

N
P 534
NEOADJUVANT CHEMOTHERAPY COMBINED WITH TARGETED TREATMENT IN HIGH-RISK RETROPERITONEAL SARCOMA – A PROSPECTIVE NON-RANDOMIZED CONTROLLED MULTI-CENTERED STUDY ALL ACROSS CHINA

Favorite
P 218
NEOADJUVANT CHEMOTHERPAY AND RADIATION DECREASES TUMOR SIZE, VIABILITY, AND RECURRENCE IN MULTIPLE LIPOSARCOMA SUBSETS

Favorite
P 31
NEOADJUVANT IMATINIB IN LOCALLY ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST) IS EFFECTIVE AND SAFE: RESULTS FROM A PROSPECTIVE SINGLE CENTER STUDY WITH 108 PATIENTS

Favorite
P 545
NEOADJUVANT PEMBROLIZUMAB AND EFTILAGIMOD ALPHA WITH CONCURRENT RADIOTHERAPY IN PATIENTS WITH SELECTED SOFT TISSUE SARCOMA SUBTYPES (EFTISARC-NEO)

Favorite
P 415
NEOADJUVANT RADIOTHERAPY MODULATES THE TUMOUR MICROENVIRONMENT OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA

Favorite
P 267
NEW MOUSE MODEL OF SYNOVIAL SARCOMA BASED ON CONDITIONAL EXPRESSION IN MESENCHYMAL PROGENITORS

Favorite
P 380
NEXT GENERATION SEQUEINCING REVEALS TARGETABLE MUTATIONS IN MULTIPLE SARCOMA HISTOLOGIES

Favorite
P 390
NOVEL ISOFORM DISCOVERY IN SARCOMA USING FULL-LENGTH PACBIO ISO-SEQ

Favorite
P 232
NOVEL MRI SCORING SYSTEM TO ASSESS OSSEOUS MALIGNANCY IN SOFT TISSUE SARCOMA PATIENTS FOLLOWING RADIOTHERAPY

Favorite
P 382
NTRK1/2/3 FUSIONS DETECTION USING RNA-SEQ IN MESENCHYMAL TUMORS REVEALS ULTRA-RARE AND HISTO-SPECIFIC TARGETABLE ALTERATIONS: EXPERIENCE OF AN EXTENSIVE ROUTINE RESEARCH PROGRAM.

Favorite